Identifying microRNAs Possibly Implicated in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia: A Review.
Tsamou, Maria, Kremers, Fabiënne A C, Samaritakis, Keano A et al. · International journal of molecular sciences · 2024 · DOI
Quick Summary
This review examined tiny molecules called microRNAs that may play a role in ME/CFS and fibromyalgia. Researchers looked at existing studies to identify which microRNAs appear to be abnormal in these conditions and what role they might play in causing symptoms. They found that certain microRNAs may be involved in immune system problems, energy production difficulties, and increased pain sensitivity—processes that could help explain why people with these diseases experience fatigue, pain, and other symptoms.
Why It Matters
This research offers a potential molecular framework for understanding ME/CFS and fibromyalgia by identifying specific biological markers that could eventually lead to objective diagnostic tests and targeted treatments. Currently, both diseases lack validated biomarkers, contributing to underdiagnosis and delayed treatment, so identifying candidate microRNAs represents an important step toward addressing this clinical gap.
Observed Findings
Nine key dysregulated microRNAs were identified: miR-29c, miR-99b, miR-128, miR-374b, miR-766, miR-23a, miR-103, miR-152, and miR-320
Identified microRNAs are associated with immune response dysfunction, mitochondrial dysfunction, oxidative stress, and central sensitization
Substantial overlap exists in dysregulated microRNAs and pathophysiological processes between ME/CFS and fibromyalgia
Both conditions share common dysregulated biological and molecular processes contributing to overlapping symptomatology
Inferred Conclusions
Dysregulated microRNAs show promise as potential biomarkers for ME/CFS and fibromyalgia
ME/CFS and fibromyalgia likely share common underlying molecular pathological mechanisms
MicroRNA-based approaches could provide new strategies for early diagnosis and therapeutic development for these medically unexplained chronic diseases
Remaining Questions
Can any of these microRNAs reliably distinguish ME/CFS from fibromyalgia or from other conditions with overlapping symptoms?
Do dysregulated microRNAs represent a primary cause of these diseases or secondary consequences of the disease process?
Which of these candidate microRNAs would be most practical and cost-effective for use in clinical diagnostic testing?
What This Study Does Not Prove
This review does not prove that any of these microRNAs actually cause ME/CFS or fibromyalgia, nor does it establish causation rather than correlation. It does not provide clinical validation that measuring these microRNAs would reliably diagnose either disease. The findings are based on reviewing existing studies, not original experimental data, so individual studies reviewed may vary in quality and methodology.